Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Total Non-Current Liabilities (2018 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $73.4 million as the latest value for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 5.77% year-over-year to $73.4 million; the TTM value through Dec 2025 reached $73.4 million, down 5.77%, while the annual FY2025 figure was $73.4 million, 5.77% down from the prior year.
  • Total Non-Current Liabilities hit $73.4 million in Q4 2025 for Sangamo Therapeutics, down from $81.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $400.4 million in Q1 2021 and bottomed at $68.1 million in Q2 2024.
  • Average Total Non-Current Liabilities over 5 years is $180.6 million, with a median of $86.8 million recorded in 2023.
  • Year-over-year, Total Non-Current Liabilities skyrocketed 117.66% in 2021 and then tumbled 70.56% in 2023.
  • Sangamo Therapeutics' Total Non-Current Liabilities stood at $345.4 million in 2021, then dropped by 22.88% to $266.3 million in 2022, then crashed by 69.5% to $81.2 million in 2023, then fell by 4.08% to $77.9 million in 2024, then decreased by 5.77% to $73.4 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $73.4 million, $81.4 million, and $77.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.